Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023

• Lunit to present two abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping

• Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict treatment outcomes in liver and colon cancer

SEOUL, South Korea, Jan. 18, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) today announced that it will deliver two poster presentations at the upcoming 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held in San Francisco, CA, and online from Jan. 19 – 21.

Read the full press release here.